Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene transfer into hematopoietic progenitor and stem cells: progress and problems

C E Dunbar1, R V Emmons

  • 1Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892.

Stem Cells (Dayton, Ohio)
|November 1, 1994
PubMed
Summary

Gene therapy aims to insert genes into hematopoietic stem cells. While retroviral vectors show promise, challenges remain in efficiency and safety, with adeno-associated virus (AAV) vectors emerging as a potential alternative.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT.

Bone marrow transplantation·2014
Same author

Active thrombopoiesis is associated with worse severity and activity of chronic GVHD.

Bone marrow transplantation·2013
Same author

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.

British journal of cancer·2010
Same author

Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glands.

Oral diseases·2010
Same author

Feline leukemia virus integrase and capsid packaging functions do not change the insertion profile of standard Moloney retroviral vectors.

Gene therapy·2010
Same author

AAV5-mediated gene transfer to the parotid glands of non-human primates.

Gene therapy·2009

Area of Science:

  • Hematology
  • Gene Therapy
  • Molecular Biology

Background:

  • Gene transfer to hematopoietic cells is a rapidly advancing field with ongoing clinical trials.
  • The primary objective is to integrate exogenous genes into hematopoietic stem cells.
  • Recombinant retroviral vectors are currently the primary vector type used in clinical trials for hematopoietic gene therapy.

Purpose of the Study:

  • To review the current state of gene transfer technologies for hematopoietic cells.
  • To discuss the challenges and potential solutions for retroviral and adeno-associated viral (AAV) vector applications.
  • To highlight the need for improved preclinical models for human gene therapy studies.

Main Methods:

  • Overview of recombinant retroviral and adeno-associated viral vector production.

Related Experiment Videos

  • Analysis of preclinical data from animal models.
  • Review of preliminary clinical trial data.

    • Main Results:

    • High-efficiency gene transfer into murine stem cells is achievable, but less successful in larger animals and humans.
    • Key challenges include retroviral efficiency, gene expression, insertional mutagenesis, and helper virus contamination.
    • Adeno-associated virus (AAV) vectors show potential for high titer, stable production with improved safety, but require further technological development.

    Conclusions:

    • Significant challenges in vector efficiency, safety, and production need to be overcome for widespread clinical utility of gene therapy.
    • Adeno-associated virus (AAV) vectors represent a promising alternative to retroviral vectors, pending further technological advancements.
    • Development of better preclinical models is crucial for advancing gene targeting and expression in human hematopoietic cells.